Early pregnancy loss affects an estimated 15% of all pregnancies in the United States. This treatment is designed to offer a new, safe, and effective clinical option for women experiencing early pregnancy loss. As with all medicines in development, regulatory approval is not guaranteed and timelines may shift. We are looking forward to keeping you informed on our next phases and hope you will check back soon for additional updates.